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I have a particular interest in the FDA’s draft guidance on patient-reported outcome 
(PRO) measures as I specialise in the design, development and use of such measures 
and license them to pharmaceutical companies, research organisations, academics and 
clinicians for use in clinical trials, other research and routine clinical practice. My 
measures include:  
- the Diabetes Treatment Satisfaction Questionnaire (DTSQ) in it’s status (DTSQs) 
and change (DTSQc) forms  1-6 and related measures for other conditions including 
the HIVTSQ, RTSQ, RetTSQ, GHerpTSQ, ThyTSQ 7 8-11, and the newly designed 
DTSQ-Teen and DTSQ-Parent. The DTSQs and c are fully linguistically validated 
in more than 60 language versions 
- the Well-being Questionnaire (e.g. W-BQ12)3 12-14 15 16  generic measure of well-
being is psychometrically validated for a range of populations including those who 
have diabetes (type 1 and type 2)  macular disease and growth hormone 
deficiency and fully linguistically validated in  25 language versions 
- the ADDQoL measure of the impact of diabetes on quality of life4 17 with related 
measures for other conditions including RDQoL, RetDQoL, MacDQoL, HDQoL, A-
RHDQoL, ThyDQoL, ADDQoL Teen 11 18-25 and recently designed ADDQoL Jnr (for 
5-8 year olds) and ADDQoL Jnr+ (for 9-12 year olds). The ADDQoL, MacDQoL 
and RetDQoL are linguistically validated in 16-25 language versions. 
 
I welcome the FDA guidance as a much needed source of information about the 
standards required in PRO design, linguistic validation, psychometric validation and use 
and recognise that the guidance may be very useful in encouraging good practice. 
 
I comment on issues in the order in which they first appear in the guidance and 
thereafter identify omissions that I ask be considered for inclusion. 
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Terminology, in particular ‘health status’ and ‘quality of life’: I welcome the use of 
the term ‘patient-reported outcome (PRO) measures’ in place of the ubiquitous and, 
usually inaccurate, use of ‘quality of life measures’. Previously ‘quality of life’ was used 
as an umbrella term to cover a wide range of PRO measures including measures of 
health status which are actually measuring quality of health and not quality of life. This 
distinction is important and failure to recognise the difference has led to some highly 
misleading conclusions and misguided policies. I emphasised the importance of 
distinguishing between quality of life and health status in a commentary in the Lancet in 
200126 where I gave the example of the influential UK Prospective Diabetes Study 
(UKPDS) as one which used health status measures but interpreted their findings as if 
they were measuring quality of life27. The UKDPS authors concluded that intensified 
treatment for Type 2 diabetes had no impact on quality of life and recommended 
widespread use of intensified treatment. In fact their findings showed there was no 
impact of intensified treatment on patients’ perceptions of the quality of their health and 
their quality of life was not measured.  This is a very different conclusion and a far less 
desirable one than the one reached erroneously by the UKPDS authors.  
 
Line 31 of the guidance defines a PRO as ‘a measurement of any aspect of a patient’s 
health status that comes directly from the patient...’. It seems that the FDA is here 
misusing the term ‘health status’, in the way that previously the term quality of life was 
misused, as an umbrella term to encompass a variety of other outcomes, which lines 35 
and 36 suggest include symptoms, activities of daily living and quality of life. Thus quality 
of life measures are here conceptualised as a subset of health status measures instead 
of health status being (wrongly) seen as one of a range of quality of life measures and 
still there is no recognition of the importance of distinguishing between these two key 
concepts, health status and quality of life. If the term ‘health status’ is upgraded in this 
way to take over from ‘quality of life’ as an umbrella term we will have as much, if not 
more, confusion over terminology and, worse still, patient reported outcomes will come 
to be seen as measures of health as viewed by the patient. There is a danger that 
clinical trials will be satisfied with measuring patients’ reports of symptoms and will fight 
shy of measuring what the FDA are describing as ‘extremely complex concepts such as 
quality of life’. The great advantage of the term ‘PRO’ is that it is a neutral term that 
covers all patient reported outcomes including their satisfaction with their treatment, their 
well-being, their quality of life and their symptoms and health without needing an interim 
term such as ‘health status’ to limit the definition. If the FDA  really feels the need to 
describe the kind of outcomes that PROs refer to then they might consider ‘health and 
quality of life outcomes’ which is the phrase eventually agreed upon by the Bio Med 
Journal of which I am an editorial board member. This phrase makes it clear that health 
outcomes are one form of PRO and quality of life outcomes are another and both are 
important but different, an issue discussed in the first editorial of the journal written by 
myself and the editor, Marcello Tamburini28. My only concern with this phrase, is that it is 
not clear to me where patient satisfaction with treatment fits in. Treatment satisfaction is 
not a measure of health status but nor is it, strictly speaking, a measure of quality of life 
even though it may affect quality of life. I am reassured somewhat by the fact that the 
phrase refers to ‘quality of life outcomes’ and not ‘quality of life’ per se or ‘quality of life 
measures’. However, in many ways it is clearer and simpler to refer just to ‘Patient 
Reported Outcomes’ and make it clear that these can include  symptoms, health status, 
treatment satisfaction, well-being and quality of life measures. 
 
Conceptualising quality of life: The guidance describes the concept of quality of life as 
‘extremely complex’. If we try to define what quality of life is in a way that is appropriate 
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for everyone it is indeed a very complex and perhaps an impossible task. However, if we 
follow the advice of Dick Joyce and define quality of life in terms of what the individual 
thinks it is29 and measure it using individualised measures (e.g. 30 17), it becomes a 
manageable, measurable and useful concept. It is very important for patients that clinical 
trialists do not duck the issue of measuring the impact of new treatments on the quality 
of life of individual participants in the trials and measure only the quality of their health. It 
is the bigger issue of quality of life that is most important to patients and it makes a great 
deal of difference to them if new treatments impair their quality of life or improve their 
quality of life. Only the patients can tell us how a treatment affects their quality of life 
using individualised PRO measures designed for the purpose (e.g.17 18 20 23 19).  
 
Suggestions and recommendations: On lines 57 and 58 it is said that ‘The use of the 
word should in Agency guidance documents means that something is suggested or 
recommended but not required’. I appreciate the good sense of this though in many 
instances whether something is recommended or not may depend on the particular 
measure, patient population or circumstances in which it is used. I would be inclined to 
qualify the ‘is suggested or recommended’ with ‘is generally (or usually) suggested or 
recommended’ to allow for exceptions to the usual rule. 
 
Separate measures of adverse consequences and effectiveness: Lines 153-157 say 
‘Some PRO measures (e.g. health-related quality of life instruments) attempt to measure 
both the effectiveness and the side effects of treatment. PRO instruments that are used 
in clinical trials to support effectiveness claims should measure the adverse 
consequences of treatment separately from the effectiveness of treatment.’ No 
explanation is given for this recommendation and it is unclear what the particular 
concern is here. Undoubtedly it is important for researchers to know about advantages 
and disadvantages of a treatment and detailed information about both is valuable for 
improving treatments. However, in developing individualised measures of the impact of 
diabetes and other chronic conditions on quality of life it is appropriate for patients to 
make holistic judgements about the impact of their condition including the treatment and 
any complications on separate aspects of their lives. Better that they weigh up the pros 
and cons themselves than have researchers make assumptions on their behalf. Patients 
are quite capable of making such judgements of impact even though they may be 
influenced by their view of the effectiveness of treatment and problems created by the 
treatment including side effects. We can and do measure these views separately but if 
we only use separate measures of symptoms and biomedical outcomes of effectiveness 
then we cannot know how to combine them to obtain a measure of their impact on the 
individual’s quality of life. I have found it possible and desirable to ask the patient to tell 
us about the impact of their condition and its treatment on their quality of life. Lines 153 
to 156, without explanation, appear to contradict my research experience. 
 
Quality of life in the taxonomy of PROs: Quality of life does not appear in Table 1. 
The use of the term ‘Overall health status’ rather confirms my concern that the FDA is 
substituting global misuse of the term ‘quality of life’ for global misuse of the term ‘health 
status’. It is very important to recognise that health status measures are needed but they 
are not everything. Quality of life measures are an essential subset of PRO measures for 
which health status measures provide no substitute.  
 
Modification of PRO instruments: I welcome efforts to discourage users of established 
validated instruments from tinkering with the wording of questionnaires unnecessarily 
while referring to the validation of the original instruments as evidence for the modified 
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instrument’s validity and reliability (lines 176-181). However, with some instruments, 
such as the DTSQc, it is necessary to modify the instructions to relate specifically to the 
conditions of the clinical trial in which it is being used and we now have considerable 
evidence to show that the psychometric properties of the DTSQc remain robust to such 
changes6 5. I encourage users of the DTSQc to check the psychometric properties on 
each new use but would not go as far as to say that each new use (with modified 
instructions) should be treated as if it is a new measure. 
 
Use of single item measures of a general concept: (lines 212-225) While it may often 
be true that ‘a single-item PRO instrument is usually unable to provide a complete 
understanding of the treatment’s effect because a single item cannot capture all the 
domains of the general concept.’ (lines 214-6), my experience of a single-item measure 
of quality of life (In general my present quality of life is…excellent through to extremely 
bad)11 18 19 20 21  23 25 suggests such an item can be valuable alongside other              
measures (eg 31 32). Indeed a single item such as this may capture all domains of the 
general concept far better than an inadequate subset of items can do (e.g. without the 
single thermometer item, the brief health status tool such as the EQ5D33 would be 
completely inadequate (instead of just inadequate) for measuring health status in the 
many people with Type 1 diabetes because its limited domains include some that are not 
impacted at all for most of this population (e.g. mobility, self care, usual activities, and 
pain/discomfort) while issues of major importance, like the problems of nocturnal 
hypoglycaemia, and of dietary restriction are omitted.) 
 
Responses to an individual item within a questionnaire are not to be allowed to support a 
claim for improvement in the individual item domain unless further items were developed 
to measure the concept. I can understand this if there was no significant improvement in 
responses to the individual item, even though there was significant improvement to the 
overall score on the questionnaire, to which the individual item contributed. However, if 
the individual item also improved significantly it would seem appropriate that such an 
improvement be used to support a claim. It is often the case that the treatment 
satisfaction score obtained by summing the 6 treatment satisfaction items on the DTSQ 
shows significant improvements with a new treatment and that one or more of the items 
that make up the measure also improve significantly. If the item concerning the 
convenience of treatment is the only one to improve significantly it is not unreasonable to 
claim that improvements in treatment satisfaction were mainly due to the convenience of 
the treatment without the need to spend years developing a separate measure of 
convenience of treatment with multiple items measuring different aspects of 
convenience. 
 
Hypothetical responses to items: Lines 302-3 say that ‘items that ask patients to 
respond hypothetically …are not recommended’. The examples given make good sense 
and I would support the FDA’s specific recommendations. However, there are 
circumstances where we have found that items that elicit hypothetical responses are 
appropriate and valuable. In the ADDQoL individualised measure of the impact of 
diabetes on quality of life, people with diabetes are asked to respond to items such as ‘If 
I didn’t have diabetes my working life would be…’ with response options ranging from 
‘very much better’ to worse. In initial qualitative work it was found that such items elicited 
more responses indicative of negative impact of diabetes on quality of life than did items 
without the hypothetical element such as ‘Because of my diabetes, my social life is…’. 
The latter, more direct approach appeared to trigger optimistic coping responses 
fostered by messages emphasised by support organisations such as Diabetes UK and 
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the American Diabetes Association which encourage people with diabetes to feel that 
most if not all their desires and ambitions can be fulfilled even though they have 
diabetes. Thus people would be likely to reply to the straightforward item asking about 
the impact of their diabetes on their social life that their diabetes has no impact on their 
social life. However, when we followed up such questions by asking ‘But if you didn’t 
have diabetes how would that affect your social life?’ people would reply ‘Ah well, yes it 
would be easier, I wouldn’t have to worry about how long we were going to be in the bar 
before we went on to eat dinner and whether I could risk injecting insulin 30 minutes 
before I ate or if the food might be late in coming and I would become hypoglycaemic 
and upset my friends by becoming irritable’. Thus we have found that people who have 
spent their lives being as positive as they can be about their chronic condition can 
usefully be encouraged to give more realistic responses stripped of the usual positive 
spin when we use the hypothetical question. It is important to note that where the aspect 
of life under consideration is not applicable to everyone (e.g. working life or sex life) 
there is the opportunity to skip the item. I would be glad if the FDA would ensure that 
their appropriate caution about some hypothetical items does not result in a blanket 
boycott of questionnaires which include hypothetical items. 
 
Comparison of present state with an earlier state: In lines 339 to 343 the FDA warns 
against instruments that rely on patients’ memory in recalling experiences over a period 
of time: ‘It is usually better to construct items that ask patients to describe their current 
state than to ask them to compare their current state with an earlier period..’. While this 
may often be good advice there are exceptions. Where measurement of patient 
satisfaction with treatment is concerned we often find that patients report being very 
satisfied with their current treatment until they experience a better treatment and then 
they want to be able to say that they are much more satisfied with the new treatment. If 
they have been given a status measure of treatment satisfaction at baseline and given 
optimum responses showing they are very satisfied, they will not be able to respond any 
more positively at follow up when they are using a new treatment with which they are 
much more satisfied. It was to overcome such ceiling effects with the DTSQs status 
measure of satisfaction with diabetes treatment that I designed and developed the 
DTSQc measure of change in treatment satisfaction for use at follow up. This allows 
patients to say that they were very satisfied at baseline with the treatment they were 
using prior to the trial but are very much more satisfied with the new treatment they 
experienced within the trial. The DTSQc is also valuable in cross over trials at the end of 
each treatment period. I have encouraged users of the DTSQc to design their trials so 
that the period over which respondents are asked to think back is a straightforward time 
period such as 12 months or 6 months and not overly precise periods such as 23 weeks. 
We also tailor the instructions to remind patients of the particular treatment change (e.g. 
‘when you started to use inhaled insulin) when trial designs involve complexities like 
screening periods. We are finding that the DTSQc provides valuable data when used in 
addition to the DTSQs that overcomes ceiling effects that are sometimes found when the 
DTSQs is used alone6 5.  
 
Asymmetric response options: Lines 367-369. It is suggested quite appropriately that 
response options should not bias the direction of responses. However, the example 
given suggests that by offering one negative choice, one neutral choice and two or more 
positive choices on a scale, it will make it more likely that patients will respond that they 
feel or function better. I have actually changed the symmetric response options originally 
used in the ADDQoL to asymmetric response options because respondents rarely used 
the response options which indicated that their quality of life would be worse if they didn’t 
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have diabetes as few people see any benefits of having diabetes. Instead of having 
seven response options, very much better, much better, a little better, the same, a little 
worse, much worse and very much worse, the three response options indicating that life 
would be worse without diabetes are now reduced to a single response option, worse. 
Thus we now have a total of 5 response options: very much better, much better, a little 
better, the same, worse. This works well. We have to have one worse option as a small 
minority of people do want to indicate benefits of having diabetes (e.g. they are 
physically fitter because they do more exercise than they would if they didn’t have 
diabetes; their social life has improved through membership of Diabetes UK) but we 
don’t need more than one option. The change to asymmetric response options was first 
made to the MacDQoL and RetDQoL for people with macular disease and diabetic 
retinopathy because it was particularly important that people with visual impairments 
should not be given more to read than absolutely necessary. Subsequently the change 
was also made to the ADDQoL in the interests of simplifying the questionnaire. In the 
case of the ADDQoL, MacDQoL and RetDQoL the numbers using the worse response 
options were small anyway and we haven’t systematically examined the change before 
and after reducing the number of response options but we can do this. It is possible that 
the number of people using the worse options decreased slightly but if so it is more likely 
because they had previously used the worse end of the scale in error when they meant 
to use the better end when there were equal numbers of response options at either side 
of the scale. We may therefore see a small improvement in internal consistency with the 
asymmetric response options alongside any decrease in use of the worse end of the 
scale.  
 
Development of format, instructions and training: Lines 390-394 specify changes to 
an instrument that might alter or influence patients’ responses. I fully support the 
statement (lines 396-398) that ‘It is important that the PRO instrument format used in the 
clinical trial be consistent with the format that is used in the instrument validation 
process. Format refers to the exact appearance of the instrument…’. The setting of a 
standard questionnaire into a commercial organisation’s format with e.g logo, questions 
situated within a frame, additional material in footer or header can frustrate some 
respondents e,g. visually impaired people, and distract others. We have been careful to 
format our vision-related questionnaires (e.g. MacDQoL and RetDQoL) to optimise ease 
of completion. When they are adapted to accommodate a company’s questionnaire 
‘livery’ the result can be a questionnaire that may be less easy for a visually impaired 
person to complete, leading to missing data or even withdrawal from the study unless 
the problem can be overcome by the use of interviewers. Companies can be very 
insistent that their format be adhered to but it may be to the detriment of the project. 
There is now pressure to produce versions of my questionnaires in a revised format 
specified by one of the major pharmaceutical companies to facilitate electronic 
regulatory submissions to the FDA. It is not clear to me how much the revised format is 
stipulated by the FDA and how much is driven by the preferences of the pharmaceutical 
company. The changes required will probably not cause problems in completion. 
However, the changes are fairly extensive and psychometric analysis will be needed to 
establish equivalence to the original version developed. I don’t think it is necessary to 
treat the new version as if it is a new questionnaire but it will be necessary to conduct 
confirmatory factor analysis to check that the psychometric properties are not affected by 
the changes made. 
 
Response burden Line 449 stipulates ‘Questions that patients are unwilling to answer’ 
may contribute to respondent burden. It is possible that patients are coerced into 
© 4th April 2006: Clare Bradley, PhD, Professor of Health Psychology,  
Royal Holloway, University of London, Egham, Surrey, TW20 0EX UK 7 
responding to questions they do not find acceptable by the setting in which they are 
asked. In research with visually impaired patients, time trade-off (TTO) questions are 
sometimes asked during hospital appointments after the patient has had his/her eyes 
dilated prior to the consultation with the ophthalmologist. Patients may feel vulnerable 
and disempowered in this situation and unable to decline to respond to difficult questions 
to which they may have personal or moral objections. Response rates may therefore 
erroneously suggest that patients were freely willing to participate. Mitchell and Bradley 
34 reported a poor response rate for TTO questions when they were administered by 
telephone to participants who were in their own homes at a time convenient to the 
participants and comments from some of those people suggested that they found the 
questions ridiculous, too hypothetical or objectionable for religious or moral reasons 34. 
These same participants completed the MacDQoL measure without any objections or 
difficulties35 showing that problems were specific to the TTO questions. 
 
Minimum important difference (MID): Table 4.  I agree that it can be helpful to 
consider the MID for clinical measures which are intermediate outcomes that may not be 
important outcomes for the patient in themselves but only in so far as they are predictors 
of other outcomes that are important (e.g. HbA1c measures of blood glucose control in 
diabetes). With some PRO measures that ask about symptoms, health status or visual 
functioning without asking about the importance of the issue in question for the patient, it 
may also be important to determine MID. However, when PROs have been designed to 
measure the importance of the aspect of life in question for the individual’s quality of life 
as well as the impact of the condition on that aspect of life, there is no need for any 
additional information about MID. A statistically significant difference between treatment 
groups on the ADDQoL, RetDQoL, MacDQoL and related measures shows that the 
differences are not due to chance and we know from the patient’s own responses how 
important the issues are to them. With treatment satisfaction items it is always possible 
that items have been selected to ask about aspects of treatment that are not considered 
important to the patients and it is necessary to establish how the items were generated 
and whether there are data on the importance of these items to patients. In the case of 
the –TSQ measures modelled on the DTSQ for diabetes, items were originally designed 
on the basis of qualitative work to establish the characteristics of the treatment important 
for patient satisfaction and dissatisfaction. In addition at least one study has been 
conducted to determine empirically the importance of each item in the DTSQ for the 
patient responders and all items were shown to be of high importance (Singh PhD 
thesis, Royal Holloway, University of London, in preparation). In such circumstances 
where the importance of the items is well established in design work and subsequent 
studies and the overall outcome being measured is not an intermediate outcome but one 
that is important to patients in its own right, it may be enough to show that there is a 
statistically significant difference between the treatment arms on this outcome measure. 
Of course a significant difference in the outcome will be easier to obtain if the sample 
size is great and it will be helpful to know the size of the effect in interpreting the results 
and compare this across studies. In sum, a statistically significant difference on 
measures of treatment satisfaction and well-being that have been designed to measure 
issues of importance to patients will necessarily be an important difference. So too will 
be a statistically significant difference on an individualised measure of the impact of a 
condition on quality of life, where the importance of an aspect of life for an individual’s 
quality of life is part of the assessment. 
 
I was not impressed with the list of ways in which people have attempted to derive MIDs 
that the FDA has reviewed and the comments made by the FDA suggested that they 
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have serious reservations too (lines 554-564). I also have major concerns about the first 
method outlined (551-554) which was not commented on by the FDA. This method 
involved mapping changes in PRO scores to clinically relevant and important changes in 
non-PRO measures and suggests that PRO measures be judged by their similarity to 
non-PRO measures such as spirometry scores in asthma. If this were appropriate there 
would be no purpose in measuring PROs at all. We might as well rely entirely on 
objective clinical measures. However, while it may be appropriate to expect some PRO 
measures such as those measuring health status or visual function to map onto clinical 
measurements, it is not appropriate for other PROs such as patient satisfaction or well 
being or the impact of the condition on quality of life which depend on much more than 
the clinical outcomes achieved. These latter PROs will depend on the demands of 
treatment and the extent to which the treatment can be adapted to suit the individual 
without damage to quality of life. It is important that we should be able to measure these 
PROs without being required to show that they map onto non-PROs! Indeed, it is 
perfectly possible that despite bringing about improvements in clinical outcomes a new 
treatment causes greater negative impact on treatment satisfaction and quality of life 
and, if so, patients are unlikely to be able to maintain clinical improvements in the long 
term.  
 
The assessment of measurement properties This section includes many important 
issues but one that is notably absent is any requirement for empirical evidence for the 
structure of a measurement that is deemed to have subscales. It is a common practice 
to design subscales to measure concepts that are theoretically rather than empirically 
derived and then to establish the measurement properties of the subscales without 
seeking evidence from principal components analysis or other such methods that the 
instrument does indeed split into the subscales as expected. The authors of the chapter 
on the DQOL (Diabetes Quality of Life) measure did not provide evidence for the 
subscales which supposedly made up the measure although they provided suitable 
evidence for the measurement properties for each of the subscales35. Subsequent work 
that has looked for supporting evidence for the presence of the intended subscales using 
factor analysis has been unsuccessful in finding such support36. I think that it is important 
to encourage questionnaire developers to provide evidence for the structure of the 
questionnaire in terms of any identifiable subscales. 
 
Modification of an existing instrument: I would welcome a stronger message to 
encourage pharmaceutical companies to use PRO measures exactly as supplied by 
scale developers and not to reformat them in their house style giving priority to logos and 
headers at the expense of font size and clarity. Whenever clients want to retype 
questionnaires it takes many rounds of review and requests for changes before all errors 
are removed and potential problems resolved with the original format preserved. I have 
never yet seen one of my questionnaires retyped without problems being introduced and 
resolving these problems is time consuming and difficult. On one occasion a major 
pharmaceutical company expected to be able to reformat a questionnaire in their house 
style despite having signed a licence agreement requiring that no changes be made to 
the questionnaire. They did not think of the style modifications as ‘changes to the 
questionnaire’. See also related points in paragraphs above ‘Modifications of PRO 
instruments’ and ‘Development of Format, Instructions and Training’. 
 
Protocol: Line 711 stipulates that the protocol include the ‘exact format and version of 
the specific PRO instrument to be administered’. While agreeing that this is essential for 
judging the suitability of the PRO I also find it essential to include a ‘For Information 
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Only’ banner across versions of my PRO measures to be included in protocols and 
ethics committee submissions to reduce the risk of unauthorised use. It would be helpful 
if the FDA would explicitly acknowledge that such banners are acceptable providing the 
whole of the questionnaire can be seen through it. 
 
Linguistic validation (LV) of PRO measures: I have already noticed that some major 
pharmaceutical companies who have previously paid only lip service to the need for 
linguistic validation, are now accepting that this is a task for specialists that will take 5 
months and may cost as much as 20,000 Euros for one questionnaire to be fully 
linguistically validated in one language by specialists in the field. I believe that 
awareness that the FDA was preparing guidance has encouraged awareness of the 
need for professional LV work. I have long collaborated with Mapi in Lyon on such work 
and work closely with them to help ensure excellent results. Some pharmaceutical 
companies want to use very much cheaper competitors who promise to complete the 
work in a fraction of the time Mapi take, but experience has shown that Mapi’s high 
standards cannot be met at such speed. I think it would be helpful to provide rather more 
guidance on the quality of LV work required to produce good translations of PRO 
measures. In particular it would be helpful to note that it is good practice for the 
developer of the measure to be closely involved in the LV work. I employ a full-time 
linguist to manage my collection of translations and she and I are actively involved in LV 
work on my questionnaires.  
 
Blinding and randomisation: I must take issue with the statement that ‘open-label 
studies, where patients and investigators are aware of assigned therapy, are rarely 
credible.’ (line 717-8). In chronic disorders such as diabetes, all participants in trials will 
receive active treatment and the issue is more often whether they receive a new 
treatment or continue with an existing treatment rather than whether they receive active 
treatment or placebo. New treatments may carry risks and possible unwanted effects as 
well as benefits and it is not appropriate to assume that patients will always be more 
positive about a new treatment than about an old treatment. It is said on line 721 that 
‘Every effort should be made to assure that patients are masked to treatment 
assignment throughout the trial’. In practice this may mean that patients are asked to 
use two treatments, one of which is a placebo. This places additional demands on the 
patients that do not reflect the clinical realities of either treatment and render the trial 
unsuitable for evaluating the impact of treatments on patient satisfaction or quality of life. 
While I agree that ‘The impact of unblinding is important to consider in the interpretation 
of study results’ (line 723) it is equally important to consider the impact of blinding on 
study results. Blinding should not be assumed to be universally desirable and in itself 
can distort study results. 
 
Line 726 suggests that ‘questions that ask how patients’ current status compares to 
baseline seem likely to be more influenced by unblinding (optimism can readily be 
expressed as a favourable comparison) than questions about current status (which 
requires a current assessment, not a statement about duration)’ (Do you mean 
differences rather than duration here?) It is particularly frustrating that there is no 
reference given for evidence for this point. In my experience of using the DTSQs (status 
measure) and the DTSQc (change measure) we often see that the DTSQc shows 
greater improvements in satisfaction with treatment than are shown by the DTSQs. 
However, separate analysis of patients who scored at or near ceiling on the DTSQs at 
baseline and patients who had more room to show improvement in  
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satisfaction showed clearly that ceiling effects were limiting the benefits shown when the 
status measure alone was used and the DTSQc provided a more accurate 
representation of the benefits patients experienced 5. It is possible that other studies 
showing fewer benefits with status measures than with change measures are in fact 
underestimating the benefits of treatment due to ceiling effects with the status measures 
that are overcome by using change measures.  
 
Avoiding missing data due to withdrawals: It can be valuable to include an early 
interim PRO data collection point in a clinical trial, say at 6 or 8 weeks, after patients 
have overcome any initial teething problems with their treatment, so that there is more 
likely to be an on-treatment endpoint measure for participants who drop out before the 
planned end of the study. Such data, together with subsequent interim data points, are 
anyway useful to track changes in such outcomes as treatment satisfaction during the 
course of a trial. A steady increase in treatment satisfaction across a 6 month or one 
year trial (e.g. 37) removes any concerns that treatment satisfaction may have increased 
initially on a new treatment as a result of optimism that subsequently turns to 
disappointment with a consequent reduction in treatment satisfaction. A progressive 
increase in patient satisfaction provides reassurance that responses are based on 
experience rather than expectations. 
 
Statistical considerations for patient-level missing data: Line 1004 refers to 
imperfect strategies that ‘try to predict missing outcomes for a patient who has 
withdrawn from the trial using data from subjects* who stayed in the trial and for whom 
all data have been collected’. Participants who withdraw from trials are likely to have 
worse scores on PROs such as treatment satisfaction measures than are those who 
continue in a trial and to impute missing values for those who withdraw from those who 
remain is likely to overestimate patient satisfaction. It would be much more informative to 
give the PRO measure to participants who withdraw early or to include interim data 
collections of PROs for use in endpoint analyses as suggested above. 
*Subjects: The British Psychological Society advises that the term ‘subjects’ not be 
sued as it can cause offence and suggests to some potential participants that they may 
be subjected to unpleasant experiences. I now avoid the term and use ‘participants’, 
‘respondents’ or ‘individuals’. The FDA might wish to follow suit and avoid all use of the 
term ‘subjects’ in these guidelines. 
 
Glossary  
Health-related quality of life (HRQL) is defined as ‘A multidomain concept that 
represents the patient’s overall perception of the impact of an illness and its treatment. 
An HRQL measure captures, at a minimum, physical, psychological (including emotional 
and cognitive), and social functioning. Claiming a statistical and meaningful improvement 
in HRQL implies: (1) that the instrument measures all HRQL domains that are important 
to interpreting change in how the study population feels or functions as a result of 
treatment; and (2) that improvement was demonstrated in all of the important domains.’ 
This definition would seem to allow for some health status measures (which measure 
quality of health) to be classed as HRQL measures (e.g. SF-36 for some patient groups) 
as well as condition-specific quality of life measures (e.g. ADDQoL 4 17). I think this 
encourages health status measures to be mislabelled as if they were quality of life 
measures (or health-related quality of life measures) when they are measures of the 
quality of health and creates problems of interpretation discussed above and 
elsewhere26 . 
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Point (1) above will exclude many generic tools which do not adequately assess the 
impact of specific conditions on aspects of life important for quality of life: this may be an 
important step forward. For example, the aspect of life measured by the ADDQoL that is 
most impaired by diabetes is freedom to eat as I wish, is not measured by any other 
quality of life measure that I am aware of. Awareness of this major influence of dietary 
restrictions on quality of life led to the evaluation of the DAFNE (Dose Adjustment For 
Normal Eating) approach to insulin treatment for diabetes with major benefits to quality 
of life, treatment satisfaction and glycaemic control 32. The DAFNE approach was 
supported by the recent National Service Framework for Diabetes in the UK and the 
Department of Health has funded roll out of the approach nationwide. 
Point (2) above: I would take issue with the suggestion that improvement needs to be 
demonstrated in all of the important domains in a HRQL instrument. First because 
improvement can only be demonstrated in domains where deficits are apparent to start 
with, however important the domain may be, and we cannot expect that deficits will 
always be found for all important domains in all uses of a questionnaire. Secondly it 
seems unreasonable to expect to see benefits for all important domains even if there 
were deficits to start with. The outstandingly successful DAFNE approach did not 
achieve significant improvements for all the domains of the ADDQoL even though it 
showed significant benefits on the overall score and on many specific domains 32. Just 
as we wouldn’t reject a treatment because not all blood measures showed 
improvements so too we should not reject a treatment because not all domains of a PRO 
measure improve.  
 
Quality of Life is defined in the glossary as ‘A general concept that implies an 
evaluation of the impact of all aspects of life on general well-being. Because this term 
implies the evaluation of nonhealth-related aspects of life, it is too broad to be 
considered appropriate for a medical product claim’. Surely it should be the ultimate aim 
of a treatment to benefit patients’ quality of life? We may sometimes have to settle for 
reducing the damage done to quality of life by a medical condition such as diabetes but 
we will still need a definition of quality of life. The ADDQoL provides an overview 
question about quality of life per se as well as measuring the impact of diabetes on 
quality of life and there have been at least two studies which have shown significant 
benefits to quality of life on the overview present quality of life item as well as reductions 
in the negative impact of diabetes on quality of life 31 32. The definition of quality of life 
that I use and have used as a basis for the design of my ADDQoL and related measures 
is that quality of life is what the individual thinks it is. The individual’s view of their quality 
of life may indeed include aspects of life that are not health related although as medical 
conditions become more severe and/or their treatment becomes more demanding and/or 
invasive, the aspects of life that are not health related diminish. I believe it is essential 
that we face up to the importance of defining and measuring quality of life per se and do 
not duck this issue or confuse matters further by defining quality of life in terms of well-
being which is a term that is not defined in the glossary! There are many measures of 
well-being which typically include subscales to measure depression and anxiety, energy, 
and, sometimes, positive well-being (e.g.12 16). When a person is depressed and anxious 
their quality of life is also likely to be impaired. However, someone who is not depressed 
or anxious may nevertheless feel that their quality of life would be much improved if they 
didn’t have diabetes. Thus measures of well-being are no substitute for measures of 
quality of life. I recommend that the FDA adopt a simple patient-centred definition for the 
concept of quality of life – quality of life is what the individual concerned thinks it is 29  
and encourages the considerable efforts made to date to measure individualised quality 
of life (e.g. the SEIQoL30) and the impact of medical conditions on individual’s quality of 
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life ( e.g. the ADDQoL 17) which have already been welcomed by several reviewers 
despite the first publication of the ADDQoL being only six years old. 38 39 40. 
 
Copyright: No mention is given of the need to respect copyright in questionnaires. Even 
major pharmaceutical companies have sometimes translated and used questionnaires 
without a licence and there needs to be clear guidance about this issue. Some authors 
of questionnaires have unwittingly caused confusion by declaring their measures ‘in the 
public domain’ and not coordinating linguistic validation work or improvements such that 
we find a proliferation of slightly different versions. If authors do not want to accept the 
responsibility for managing the questionnaire, they might be encouraged to subcontract 
that task to another organisation that specialises in such work (e.g. Mapi Research 
Institute in Lyons). There has recently been an increased demand for linguistic validation 
certificates documenting the procedures used in the linguistic validation work to produce 
new language versions of questionnaires and I believe this has been driven by the 
demands of the regulatory bodies. It certainly seems to be a useful way of discouraging 
unauthorised translations and ensuring that only authorised translations are sought and 
used. The FDA is in an excellent position to encourage good practice in obtaining PROs 
from copyright holders and discouraging unlicensed use. 
 
References are needed: Lack of references to the examples given in the FDA 
guidelines makes it very difficult to accept a number of recommendations which appear 
to be over generalising from specific cases when that is not justified.  For example, line 
726 says ‘questions that ask how patients’ current status compares to baseline seem 
likely to be more influenced by unblinding (optimism can readily be expressed as a 
favourable comparison) than questions that ask about current status..’  This may be a 
misinterpretation of ceiling effects leading to smaller changes with status measures than 
are seen with change measures. My investigations of such measures lead me to believe 
that the change measures give the more accurate reflection of patients’ experiences as 
discussed above in the section on Blinding and Randomisation. A colleague who 
attended a meeting to discuss these guidelines with representatives from the FDA 
commented that when questions were raised about generalities made in the guidelines 
the answers always started with ‘It depends…’. It would seem to make very good sense 
to acknowledge that many of the general points will depend on the particular 
circumstances and the provision of references would recognise the importance of 
providing evidence for recommendations and leave open the possibility that there may 
be other evidence which would support different conclusions. 
 
Access to questionnaires, questionnaire guidelines and references: I will be glad to 
provide e-copies of any of my questionnaires listed on page 1 of these guidelines, and 
associated scoring instructions, user guidelines, and reference lists and can be 
contacted at the address in the footer or by email at c.bradley@rhul.ac.uk.  
 
Summary: I believe that the FDA guidelines have already had an impact in encouraging 
good practice in the use of PROs. There are, however, important improvements that 
need to be made to the guidelines, particularly in the use of health status and quality of 
life terminology. It is essential to distinguish between health status and quality of life and 
to use both terms. Nothing is to be gained and a great deal will be lost if the term quality 
of life (which has been misused as an umbrella term in the past) is abandoned and 
replaced with the term health status. Patients want us to consider their quality of life as 
well as their health. To abandon the term would be to forget about their quality of life and 
focus only on their health. Patients are well able to tell us what quality of life means to 
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them and to rate the impact of a condition on their quality of life if we use individualised 
quality of life measures (e.g.30) and individualised condition-specific quality of life 
measures (e.g.4) to allow them to do so. Although my experience with PRO measures 
would support many of the recommendations in the guidelines there are others that I 
would not fully agree with or would contradict on the basis of my own research evidence. 
I have provided references to that research and hope that the FDA will feel able to do 
the same when they finalise these guidelines.  
 
 
 
 
References 
 
1. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction 
developed from the responses of people with tablet-treated diabetes. Diabetic 
Medicine 1990;7:445-451. 
2. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: (DTSQ). In: Bradley 
C, editor. Handbook of Psychology and Diabetes: a guide to psychological 
measurement in diabetes research and practice. Chur, Switzerland: Harwood 
Academic Publishers, 1994:111-132. 
3. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of 
a Working Group of the World Health Organization Regional Office for Europe 
and International Diabetes Federation European Region St Vincent Declaration 
Action Programme for Diabetes. Diabet Med 1994;11(5):510-6. 
4. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing 
quality of life. Diabetes Metab Res Rev 2002;18 Suppl 3:S64-9. 
5. Bradley C, Plowright R, Stewart J, Witthaus E. Diabetes Treatment Satisfaction 
Questionnaire (change) in English and German evaluated in insulin glargine 
trials. Diabetologia 2000;43(1):A196. 
6. Howorka K, Pumprla J, Schlusche C, Wagner-Nosiska D, Schabmann A, Bradley C. 
Dealing with ceiling baseline treatment satisfaction level in patients with diabetes 
under flexible, functional insulin treatment: Assessment of improvements in 
treatment satisfaction with a new insulin analogue. Quality of Life Research 
2001;9:915-930. 
7. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire 
(HIVTSQ). Qual Life Res 2001;10(6):517-31. 
8. Barendse SM, Speight J, Bradley C. The Renal Treatment Satisfaction Questionnaire 
(RTSQ): a measure of satisfaction with treatment for chronic kidney failure. Am J 
Kidney Dis 2005;45(3):572-9. 
9. Woodcock A, Plowright R, Kennedy-Martin T, Hirsch A, Ffytche T, Bradley C. 
Development of the new Retinopathy Treatment Satisfaction Questionnaire 
(RetTSQ). Proceedings of Vision 2005; International Congress Series 
2005;1282:342-346. 
10. Taback N, Bradley C. Validation of the Genital Herpes Treatment Satisfaction 
Questionnaire (GHerpTSQ) in Status and Change Versions. Quality of Life 
Research 2000;9(3):332. 
11. McMillan CV, Bradley C, Woodcock A, Razvi S, Weaver JU. Design of new 
questionnaires to measure quality of life and treatment satisfaction in 
hypothyroidism. Thyroid 2004;14(11):916-25. 
12. Bradley C. The 12-Item Well-Being Questionnaire: origins, current stage of 
development, and availability. Diabetes Care 2000;23(6):875. 
© 4th April 2006: Clare Bradley, PhD, Professor of Health Psychology,  
Royal Holloway, University of London, Egham, Surrey, TW20 0EX UK 14 
13. Pouwer F, van der Ploeg HM, Ader HJ, Heine RJ, Snoek FJ. The 12-item well-being 
questionnaire. An evaluation of its validity and reliability in Dutch people with 
diabetes. Diabetes Care 1999;22(12):2004-10. 
14. Pouwer F, Snoek FJ, Van der Ploeg HM, Ader HJ, Heine RJ. The Well-Being 
Questionnaire: evidence for a three factor structure with 12 items (W-BQ12). 
Psychological Medicine 2000;30:455-462. 
15. Mitchell J, Bradley C. Psychometric evaluation of the 12-item Well-being 
Questionnaire for use with people with macular disease. Qual Life Res 
2001;10(5):465-73. 
16. McMillan C, Bradley C, Gibney J, Russell-Jones D, Sonksen P. Well-being in adult 
growth hormone deficiency. Health and Quality of Life Outcomes 2006;In press. 
17. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development 
of an individualized questionnaire measure of perceived impact of diabetes on 
quality of life: the ADDQoL. Qual Life Res 1999;8(1-2):79-91. 
18. Bradley C. Design of a renal-dependent individualised quality of life questionnaire. 
Advances in Peritoneal Dialysis 1997;13:116-120. 
19. Woodcock A, Bradley C, Plowright R, ffytche T, Kennedy-Martin T, Hirsch A. The 
influence of diabetic retinopathy on quality of life: interviews to guide the design 
of a condition-specific, individualised questionnaire: the RetDQoL. Patient Educ 
Couns 2004;53(3):365-83. 
20. Mitchell J, Bradley C. Design of an individualised measure of the impact of macular 
disease on quality of life (the MacDQoL). Qual Life Res 2004;13(6):1163-75. 
21. Mitchell J, Wolffsohn JS, Woodcock A, Anderson SJ, McMillan CV, Ffytche T, et al. 
Psychometric evaluation of the MacDQoL individualised measure of the impact of 
macular degeneration on quality of life. Health Qual Life Outcomes 2005;3(1):25. 
22. McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sonksen PH. 
Psychological effects of withdrawal of growth hormone therapy from adults with 
growth hormone deficiency. Clin Endocrinol (Oxf) 2003;59(4):467-75. 
23. McMillan C, Bradley C, M G, Martin F, Sonksen P. Preliminary development of a new 
individualised questionnaire measuring quality of life in older men with age-
related hormonal decline: the A-RHDQoL. Health and Quality of Life Outcomes 
2003;1(51). 
24. McMillan CV, Honeyford RJ, Datta J, Madge NJ, Bradley C. The development of a 
new measure of quality of life for young people with diabetes mellitus: the 
ADDQoL-Teen. Health Qual Life Outcomes 2004;2(1):61. 
25. McMillan C, Bradley C, Gibney J, Russell-Jones DL, Sonksen PH. Preliminary 
development of the new individualised HDQoL questionnaire measuring quality 
of life in adult hypopituitarism. Journal of Evaluation in Clinical Practice 2006;In 
press. 
26. Bradley C. Importance of differentiating health status from quality of life. Lancet 
2001;357(9249):7-8. 
27. U.K. Prospective Diabetes Study Group. Quality of Life in Type 2 Diabetic Patients Is 
Affected by Complications But Not by Intensive Policies to Improve Blood 
Glucose or Blood Pressure Control (UKPDS 37). Diabetes Care 
1999;22(7):1125-1136. 
28. Bradley C, Tamburini M. Not-only-a title. Editorial. Health and Quality of Life 
Outcomes 2003;1(1). 
29. Joyce CRB. Requirements for the assessment of individual quality of life. In: McGee 
HM, Bradley C, editors. Quality of Life Following Renal Failure: Psychosocial 
Challenges Accompanying High Technology Medicine. Chur, Switzerland: 
Harwood Academic, 1994:43-54. 
© 4th April 2006: Clare Bradley, PhD, Professor of Health Psychology,  
Royal Holloway, University of London, Egham, Surrey, TW20 0EX UK 15 
30. McGee HM, O'Boyle CA, Hickey A, O'Malley KM, Joyce CRB. Assessing the quality 
of life of the individual: The SEIQoL with a healthy and a gastroenterology unit 
population. Psychological Medicine 1991;21:749-759. 
31. Johnston P, Stephens J, Witthaus E, Bradley C. Improved treatment satisfaction and 
quality of life with insulin glargine +lispro compared with NPH insulin + regular 
human insulin. The Endocrine Society's 86th Annual Meeting Program and 
Abstract Book; 2004:397. 
32. DAFNE. Training in flexible, intensive insulin management to enable dietary freedom 
in people with type 1 diabetes: the dose adjustment for normal eating (DAFNE) 
randomised control trial. BMJ 2002;325:746 - 749. 
33. EuroQoL Group. EuroQoL - a new facility for the measurement of health-related 
quality of life. Health Policy 1990;16:199-208. 
34. Mitchell J, Bradley C. Measuring quality of life in macular disease: What use are 
utilities? International Congress Series 2005;1282:654-658. 
35. Jacobson AM, The Diabetes Control and Complications Trial Research Group. The 
Diabetes Quality of Life Measure. In: Bradley C, editor. Handbook of Psychology 
and Diabetes: A Guide to Psychologial Measurement in Diabetes Research and 
Practice. Chur, Switzerland: Harwood Academic, 1994:65-88. 
36. Eiser C, Flynn M, Green E, Havermans T, Kirby R, Sandeman D, et al. Quality of Life 
in Young Adults with Type 1 Diabetes in Relation to Demographic and Disease 
Variables. Diabetic Medicine 1992;9:375-378. 
37. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-
being with insulin glargine compared with NPH in patients with Type 1 diabetes. 
Diabet Med 2001;18(8):619-25. 
38. Polonsky WH. Understanding and Assessing Diabetes-Specific Quality of Life. 
Diabetes Spectrum 2000;13(1):17-22. 
39. Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for 
diabetes: a structured review. Diabet Med 2002;19(1):1-11. 
40. Greenhalgh J, Long AF, Brettle AJ, Grant MJ. Reviewing and selecting outcome 
measures for use in routine practice. J Eval Clin Pract 1998;4(4):339-50. 
 
 
 
